Iterum Therapeutics plc (ITRMF) Total Current Liabilities (2017 - 2025)

Iterum Therapeutics has reported Total Current Liabilities for 9 years, with the latest figure at $6.4 million in Q3 2025.

• On a quarterly basis, Total Current Liabilities fell 65.62% year-over-year to $6.4 million in Q3 2025; TTM through Sep 2025 was $6.4 million, a 65.62% decrease from a year earlier, with the FY2024 full-year figure at $17.6 million, up 30.23% from the prior year.
• Total Current Liabilities was $6.4 million for Q3 2025 at Iterum Therapeutics, up from $5.5 million in the prior quarter.
• The five-year high for Total Current Liabilities was $43.8 million in Q1 2021, with the low at $3.6 million in Q1 2025.
• Average Total Current Liabilities over 5 years is $14.6 million, with a median of $12.9 million recorded in 2021.
• The sharpest annual moves came in 2024 and 2025: Total Current Liabilities surged 128.22% in 2024, then tumbled 79.61% in 2025.
• Over 5 years, Total Current Liabilities stood at $12.9 million in 2021, then declined by 29.96% to $9.1 million in 2022, then soared by 49.14% to $13.5 million in 2023, then jumped by 30.23% to $17.6 million in 2024, then slumped by 63.48% to $6.4 million in 2025.
• The last three Total Current Liabilities figures came in at $6.4 million (Q3 2025), $5.5 million (Q2 2025), and $3.6 million (Q1 2025), per Business Quant data.